IL257439B - Methods for the differential diagnosis of adrenocorticotropic hormone-dependent Cushing's syndrome - Google Patents

Methods for the differential diagnosis of adrenocorticotropic hormone-dependent Cushing's syndrome

Info

Publication number
IL257439B
IL257439B IL257439A IL25743918A IL257439B IL 257439 B IL257439 B IL 257439B IL 257439 A IL257439 A IL 257439A IL 25743918 A IL25743918 A IL 25743918A IL 257439 B IL257439 B IL 257439B
Authority
IL
Israel
Prior art keywords
syndrome
differentially diagnosing
dependent cushing
acth
diagnosing acth
Prior art date
Application number
IL257439A
Other languages
English (en)
Hebrew (he)
Other versions
IL257439A (en
Inventor
G Moraitis Andreas
Original Assignee
Corcept Therapeutics Inc
G Moraitis Andreas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57983847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL257439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc, G Moraitis Andreas filed Critical Corcept Therapeutics Inc
Publication of IL257439A publication Critical patent/IL257439A/en
Publication of IL257439B publication Critical patent/IL257439B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G01N2333/695—Corticotropin [ACTH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/048—Pituitary or hypothalamic - pituitary relationships, e.g. vasopressin or ADH related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL257439A 2015-08-13 2018-02-08 Methods for the differential diagnosis of adrenocorticotropic hormone-dependent Cushing's syndrome IL257439B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562204723P 2015-08-13 2015-08-13
PCT/US2016/046904 WO2017027851A1 (en) 2015-08-13 2016-08-12 Method for differentially diagnosing acth-dependent cushing's syndrome

Publications (2)

Publication Number Publication Date
IL257439A IL257439A (en) 2018-04-30
IL257439B true IL257439B (en) 2020-08-31

Family

ID=57983847

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257439A IL257439B (en) 2015-08-13 2018-02-08 Methods for the differential diagnosis of adrenocorticotropic hormone-dependent Cushing's syndrome

Country Status (10)

Country Link
US (6) US9829495B2 (https=)
EP (1) EP3335043B1 (https=)
JP (1) JP6768789B2 (https=)
KR (1) KR20180052120A (https=)
AU (1) AU2016305092B2 (https=)
CA (1) CA2994422A1 (https=)
ES (1) ES2865334T3 (https=)
IL (1) IL257439B (https=)
MX (1) MX383318B (https=)
WO (1) WO2017027851A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
FI3897589T3 (fi) 2018-12-19 2026-01-13 Corcept Therapeutics Inc Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
ES3008837T3 (en) 2018-12-21 2025-03-25 Corcept Therapeutics Inc Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator
JP7789561B2 (ja) 2019-02-22 2025-12-22 コーセプト セラピューティクス， インコーポレイテッド レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
US12527818B2 (en) 2019-07-11 2026-01-20 Emory University Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (GR) binding agents, and/or HSP90 binding agents for uses in treating cancer
US20230358768A1 (en) * 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
AT18182U1 (de) * 2020-05-04 2024-04-15 Nordic Group Bv Mifepriston in oraler Form zur Verwendung bei der Zervixreifung und Geburtseinleitung
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2023301396A1 (en) * 2022-06-28 2024-12-12 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL319657A (en) 2022-10-06 2025-05-01 Corcept Therapeutics Inc Glucocorticoid receptor modulator formulations
WO2024092195A1 (en) 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5382661A (en) 1985-09-12 1995-01-17 The Upjohn Company Pyrazinylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
BE1004905A4 (fr) 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE69500542T2 (de) 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
EP1043325B1 (en) 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
WO1998027986A1 (en) 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL146057A (en) 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
WO2003043640A2 (en) 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
WO2004036377A2 (en) 2002-10-15 2004-04-29 Medtronic Inc. Configuring and testing treatment therapy parameters for a medical device system
JP2006508951A (ja) 2002-11-05 2006-03-16 コーセプト セラピューティクス， インコーポレイテッド 片頭痛を処置するための方法
PT1761497E (pt) 2004-01-09 2008-09-25 Corcept Therapeutics Inc Azadecalinas moduladoras do receptor de glucocorticóides
AU2005222421B2 (en) * 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
PT1778236E (pt) 2004-07-02 2010-10-19 Corcept Therapeutics Inc Moduladores do receptor de glucocorticóide de pirimidina modificada
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
MX2009004385A (es) 2006-10-23 2009-05-22 Merck & Co Inc Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide.
US8598149B2 (en) 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
EP2532350A1 (en) 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
ES2531040T3 (es) 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
DK2685827T3 (en) * 2011-03-18 2016-05-17 Corcept Therapeutics Inc PYRIMIDIN -cyclohexyl- glucocorticoid receptor MODULATORS
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT4119561T (pt) * 2012-05-25 2024-09-30 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
ITFI20120127A1 (it) * 2012-06-21 2013-12-22 Valpharma Internat Spa Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio, compresse così ottenute e loro processo di preparazione.
US20140170768A1 (en) * 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH

Also Published As

Publication number Publication date
KR20180052120A (ko) 2018-05-17
JP2018529941A (ja) 2018-10-11
US10006924B2 (en) 2018-06-26
US10495650B2 (en) 2019-12-03
US20200088745A1 (en) 2020-03-19
US9829495B2 (en) 2017-11-28
AU2016305092B2 (en) 2022-01-27
ES2865334T3 (es) 2021-10-15
EP3335043B1 (en) 2021-03-31
US20230324415A1 (en) 2023-10-12
US11073523B2 (en) 2021-07-27
EP3335043A1 (en) 2018-06-20
US20180267064A1 (en) 2018-09-20
MX383318B (es) 2025-03-13
AU2016305092A1 (en) 2018-04-05
HK1255714A1 (en) 2019-08-23
JP6768789B2 (ja) 2020-10-14
US20180052178A1 (en) 2018-02-22
MX2018001803A (es) 2018-05-16
EP3335043A4 (en) 2019-01-16
US20170045535A1 (en) 2017-02-16
IL257439A (en) 2018-04-30
WO2017027851A1 (en) 2017-02-16
US20210311079A1 (en) 2021-10-07
CA2994422A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
IL257439B (en) Methods for the differential diagnosis of adrenocorticotropic hormone-dependent Cushing's syndrome
DK3294906T3 (en) Methods for determining ploidy
GB201607585D0 (en) Ride-sharing joint rental groups
SG11201706094RA (en) Improving epfd coverage for ngso satellites
EP3288455C0 (en) DIAGNOSTIC PROCEDURE
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
GB201615831D0 (en) Virtual, road-surface-perception test bed
SI3412648T1 (sl) Postopek za izdelavo 1,1,3,3-tetrakloropropena
IL250682A0 (en) A method for the preparation of 2'-o-fucosyl lactose
SG11201705754QA (en) Oil-extended rubber, rubber composition, and method for manufacturing the oil-extended rubber
PL3178803T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
GB201511969D0 (en) Biosensor
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
IL259557A (en) Methods for the preparation of modified 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine
GB2540428B (en) Process for preparing 3,3,3-trifluoropropene
GB201502140D0 (en) Wheel within the wheel
PL3122717T3 (pl) Eteroaminy na bazie 1,2-dialkoholi
IL255103A0 (en) Ethinyl history
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
IL258217A (en) 2,3,4,5 tetrahydropyridin-6-amine derivatives
GB201615753D0 (en) Diagnostic method
ZA201907335B (en) Benzothiazole-containing silanes, method for the preparation and use thereof
SG11201700276QA (en) Quinoxaline compounds, method for preparing the same and use thereof
IL251229B (en) Process for preparing 5-bromo-1,2,3-trichlorobenzene
GB201513981D0 (en) Acaricides

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed